Vaccine breakthrough stops cancer returning in trial
BBC News · 2026-08-19
A new personalized cancer vaccine, developed by Merck (MSD in Europe) and Moderna, has shown promise in preventing cancer recurrence. This innovative jab utilizes mRNA technology, similar to some Covid-19 vaccines, to target specific mutations within an individual patient's tumor. Scientists achieve this by surgically removing a small tumor sample, sequencing its DNA, and then creating a tailored vaccine that instructs the immune system to recognize and attack any remaining cancer cells.
Prof Peter Johnson, National Clinical Director for Cancer at NHS England, described it as a "very important advance," highlighting its specific targeting capability compared to broader immune treatments. Stephane Bancel, Moderna's CEO, called it a "pivotal moment" for cancer research. While experts like Dr. Talisia Quallo from Cancer Research UK acknowledge its potential, they emphasize that these are interim findings and require full review. Dr. Lennard Lee, a consultant medical oncologist, confirmed its significance for melanoma patients and established the "proof of principle that personalised cancer vaccines work." More detailed findings are expected in October.
*The full article also explores the specific types of cancer these companies are testing similar vaccines for and the broader implications for personalized medicine.*